Botulinum toxin A for sialorrhea in adults with neurological disorders: a narrative review of aspiration pneumonia risk - Takeaways - MDSpire

Botulinum Toxin Type A for Managing Sialorrhea in Adults with Neurological Conditions: A Review of the Associated Aspiration Pneumonia Risk

  • By

  • Sultan Alzarouni

  • Krishab Sati

  • Prashanth Reddy

  • Mubasher A. Qamar

  • July 17, 2026

Share

  • 1

    Aspiration pneumonia (AP) is a significant concern for patients with neurological disorders due to compromised swallowing mechanisms.

  • 2

    Botulinum neurotoxin type A (BoNT-A) is identified as a potential treatment for managing sialorrhea in adults with neurological conditions.

  • 3

    Evidence supporting BoNT-A's efficacy in reducing sialorrhea is established, particularly in pediatric patients with neurological conditions.

  • 4

    Limited research exists on the direct impact of BoNT-A on reducing aspiration pneumonia risk in adults with neurological disorders.

  • 5

    Sialorrhea contributes to significant psychosocial distress and oral health deterioration in patients with neurological conditions.

Original Source(s)

Botulinum toxin A for sialorrhea in adults with neurological disorders: a narrative review of aspiration pneumonia risk

  • by Sultan Alzarouni, Krishab Sati, Prashanth Reddy, Mubasher A. Qamar

  • July 17, 2026

Related Content

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Cerebral hemorrhage after left ventricular assist device implantation in a patient with dilated cardiomyopathy: a case report

Innovations in repetitive transcranial magnetic stimulation: a review of clinical evidence and patient-reported outcomes for ExoTMS